Inhibikase Therapeutics Inc (IKT)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
The current IKT market cap is 142.88M. The company's latest EPS is USD -0.2832 and P/E is -7.38.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 80k | 0 | 0 | 0 | 0 |
| Operating Income | -4.77M | -4.4M | -4.78M | -5.05M | -5.83M |
| Net Income | -4.6M | -4.18M | -4.65M | -4.96M | -5.78M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 1.12M | 698k | 3.1M | 123k | 261k |
| Operating Income | -5.7M | -2.82M | -14.77M | -18.13M | -20.09M |
| Net Income | -5.72M | -2.85M | -14.79M | -18.05M | -19.03M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 17.88M | 14.51M | 11.07M | 8.83M | 4.38M |
| Total Liabilities | 2.86M | 3.53M | 4.29M | 3.73M | 4.91M |
| Total Equity | 15.02M | 10.98M | 6.78M | 5.1M | -531k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 38k | 14.78M | 42.47M | 24.94M | 14.51M |
| Total Liabilities | 4.53M | 5M | 4.05M | 3.9M | 3.53M |
| Total Equity | -4.49M | 9.78M | 38.42M | 21.04M | 10.98M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -14.64M | -18.09M | -3.87M | -8.92M | -13.8M |
| Investing | 13.77M | 11.66M | -3.31M | -769k | 1.76M |
| Financing | 8.54M | 8.41M | 367k | 3.61M | 3.79M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -338k | -1.13M | -14.3M | -17.35M | -18.09M |
| Investing | N/A | N/A | N/A | -16.01M | 11.66M |
| Financing | -23k | 15.07M | 41.09M | -205k | 8.41M |
| Market Cap | 142.88M |
| Price to Earnings Ratio | -7.38 |
| Price to Sales Ratio | 535.9 |
| Price to Cash Ratio | 15.32 |
| Price to Book Ratio | 12.79 |
| Dividend Yield | - |
| Shares Outstanding | 67.19M |
| Average Volume (1 week) | 170.15k |
| Average Volume (1 Month) | 189.56k |
| 52 Week Change | -2.01% |
| 52 Week High | 4.20 |
| 52 Week Low | 1.12 |
| Spread (Intraday) | 0.02 (0.93%) |
| Company Name | Inhibikase Therapeutics Inc |
| Address |
1313 n market st ste 5100 wilmington, delaware 19801 |
| Website | https://www.inhibikase.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
